(News Bulletin 247) – OSE Immuno has announced the positive verdict of a futility analysis conducted by the DSMB (Independent Drug Safety Monitoring Board) as part of its Ph II study in UC (ulcerative colitis) in patients with a moderate to severe active form.
‘This analysis focused on the first 50 patients who completed the induction phase (10 weeks of treatment), the total cohort providing for 150 patients’ specifies Invest Securities.
‘ As a reminder, the main results of this trial are expected at the end of the year for the induction phase, while data in the maintenance phase are expected in H1 2024. Positive results in UC could relaunch the OSE product -127 after Servier’s decision to return the rights earlier this year. At the same time, the EMA has granted orphan status to OSE-127 in ALL leukaemia’ indicates the analysis office.
Following this announcement, Invest Securities confirms its advice to buy with a price target of €8.2.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
